Merrill, Kaitlyn A.
Abrams, Elissa M.
Good, Sara V.
Gupta, Ruchi S.
Venter, Carina
Frykas, Tara Lynn M.
Golding, Michael A.
Protudjer, Jennifer L. P.
Funding for this research was provided by:
University of Manitoba (54342)
Article History
Received: 26 August 2022
Accepted: 23 November 2022
First Online: 6 December 2022
Declarations
:
: The study received approval from the University of Manitoba Research Ethics Board, ethics file number HS24604 (H2021:034).
: Not applicable.
: KAM declares no competing interests. EMA is an employee of Public Health Agency of Canada (PHAC); views expressed are her own and not those of PHAC. SVG declares no competing interests. RSG receives research support from the National Institutes of Health (NIH) (R21 ID # AI135705, R01 ID # AI130348, U01 ID # AI138907), Food Allergy Research & Education (FARE), Melchiorre Family Foundation, Sunshine Charitable Foundation, The Walder Foundation, UnitedHealth Group, Thermo Fisher Scientific, and Genentech. She serves as a medical consultant/advisor for Genentech, Novartis, Aimmune LLC, Allergenis LLC, and Food Allergy Research & Education (FARE). Dr. Gupta has ownership interest in Yobee Care, Inc. She is currently employed by Ann & Robert H. Lurie Children's Hospital of Chicago and is a Professor of Pediatrics & Medicine at Northwestern University Feinberg School of Medicine. CV reports grants from Reckitt Benckiser, grants from Food Allergy Research and Education, grants from National Peanut Board, during the conduct of the study; personal fees from Reckitt Benckiser, Nestle Nutrition Institute, Danone, Abbott Nutrition, Else Nutrition, and Before Brands, outside the submitted work. TLMF declares no competing interests. MG declares no competing interests. JLLP sits on the steering committee for Canada’s National Food Allergy Action Plan; is Section Head of Allied Health, Canadian Society of Allergy and Clinical Immunology; and report consulting fees for Novartis and Nutricia.